Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI Hong Kong ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Eli Lilly And Co — how do they compare? iShares MSCI Hong Kong ETF trades at $22.46, while Eli Lilly And Co trades at $1,221.25 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals.

EWHLLY
Sector
Broad Market / FactorHealth
52-Week High
$24.55$1.24K
52-Week Low
$20.66$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH trades at $22.45, down 1.54% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights the Hang Seng Index's rebound and potential golden cross formation, driven by technology stock recoveries. The ETF shows no available fundamental ratios in the provided data, but tracks Hong Kong equities, with a dividend scheduled for June 2026.

Outlook hinges on Hong Kong market performance and tech sector momentum. Risks include Asian market volatility and geopolitical factors. Analyst sentiment is mixed, with some bullish on Hong Kong over Korea, while technicals suggest caution near support at $22.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY